Price$7.57+0.35 (+4.78%)
2026-04-142026-07-17
News · 26 weeks30-89%
2026-01-182026-07-12
Mix1890d
- Insider8(44%)
- SEC Filings5(28%)
- Earnings2(11%)
- Analyst2(11%)
- Other1(6%)
Latest news
25 items- ANALYSTOppenheimer initiated coverage on Kyntra Bio with a new price targetOppenheimer initiated coverage of Kyntra Bio with a rating of Outperform and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Director Ho Maykin4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Edwards Jeffrey L4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Kauffman Michael4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Director Schoeneck James A4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- PRKyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic SyndromesIn a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placeboSimilar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) diseasePivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA) SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced additional data
- INSIDERCEO Wettig Thane covered exercise/tax liability with 198 shares, decreasing direct ownership by 0.73% to 27,005 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERChief Financial Officer Delucia David covered exercise/tax liability with 52 shares, decreasing direct ownership by 1% to 4,377 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Other Events8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Kyntra Bio with a new price targetRodman & Renshaw initiated coverage of Kyntra Bio with a rating of Buy and set a new price target of $30.00
- INSIDERAmendment: CEO Wettig Thane bought $19,852 worth of shares (2,800 units at $7.09), increasing direct ownership by 11% to 27,203 units (SEC Form 4)4/A - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERCEO Wettig Thane decreased direct ownership by 9% to 27,203 units (SEC Form 4)4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- SECSEC Form 10-Q filed by Kyntra Bio Inc.10-Q - KYNTRA BIO, INC. (0000921299) (Filer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug Admi
- PRKyntra Bio to Report First Quarter 2026 Financial ResultsSAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone,
- SECSEC Form DEFA14A filed by Kyntra Bio Inc.DEFA14A - KYNTRA BIO, INC. (0000921299) (Filer)
- SECSEC Form DEF 14A filed by Kyntra Bio Inc.DEF 14A - KYNTRA BIO, INC. (0000921299) (Filer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceSAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here. Kyntra Bio's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Needham. A replay of the presentation will be posted, when available, to the Kyntra Bio website on the Events & Presentations page of the Inves
- SECSEC Form 10-K filed by Kyntra Bio Inc.10-K - KYNTRA BIO, INC. (0000921299) (Filer)
- SECKyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KYNTRA BIO, INC. (0000921299) (Filer)
- PRKyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash
- INSIDERSEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
- INSIDERSEC Form 4 filed by Kyntra Bio Inc.4 - KYNTRA BIO, INC. (0000921299) (Issuer)
KYNB FAQ
6 questionsWhere does KYNB stock trade?
Kyntra Bio Inc. (KYNB) is listed on NASDAQ.What sector and industry is KYNB in?
Kyntra Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kyntra Bio Inc. go public?
Kyntra Bio Inc. (KYNB) completed its IPO in 2014.What are analysts saying about KYNB?
Kyntra Bio Inc. has had 2 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $3500.00 price target on 2026-07-07. Recent price targets range from $3000.00 to $3500.00.What companies are similar to KYNB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KYNB side-by-side with any of them on Quantisnow.How can I track KYNB on Quantisnow?
Quantisnow aggregates Kyntra Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYNB to receive live email and push alerts on every new disclosure.